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ABSTRACT
Background: Despite enormous advances in identifying genetic variants responsible for 
many neurological diseases, access to genetic testing access to genetic testing may be 
limited in clinical practice. 
Objectives: To assess worldwide access to genetic tests for movement disorders and 
factors impacting their utilization.
Methods: The Rare Movement Disorders Study Group of the International Parkinson and 
Movement Disorder Society designed an online survey electronically mailed to all 7815 
members. 
Results: Survey data completed by 1269 participants from 109 countries were analyzed. 
Limited access to geneticists and genetic counsellors was reported in many world regions 
compared to Europe and North America. Availability of genetic testing was limited, with rates 
of access lower than 50%. Genetic testing for chorea was the most commonly available. For 
parkinsonism, dystonia, ataxia, hereditary spastic paraplegias, and metabolic disorders, 
there was limited access to genetic testing in all countries compared to Europe and North 
America, with significant differences found for Africa, Central/South America, Asia. In many 
regions, genetic testing was supported either by private or public funding. Genetic testing 
was free of charge in Europe according to 63.5% of respondents. In North America, Africa, 
Central/South America, Asia and Middle East access to free of charge genetic testing was 
by far significantly lower compared to Europe.
Conclusions: This survey highlights difficulties in accessing genetic testing and individuals 
with expertise in genetics at the worldwide level. In addition, we highlighted major disparities 
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INTRODUCTION
During the past two decades, there have been remarkable developments in identifying 
genetic variants responsible for many neurological diseases, and parallel advances in 
clinical diagnostic testing for these diseases, especially in the movement disorders field [1]. 
Clinical diagnostic testing, initially focusing on one or a few genes at a time, have been 
replaced by much broader testing strategies, such as disease-specific gene panels [2, 3] 
and whole exome sequencing (WES).  Multiple reviews regarding the optimal use of different 
genetic tests have been published, and professional societies have devoted enormous 
efforts to education regarding the use of modern genetic testing [4-6].
Although these advances are valuable, access to genetic testing may be limited in clinical 
practice [7]. There is little knowledge regarding which factors influence access to genetic 
testing in neurological disorders and specifically in the movement disorders field. It is likely 
that lack of access might occur not only in resource-poor areas but also in those countries 
where gene panels or WES are available, but not covered by public funding or private 
insurances. It is crucial to clarify these issues in order to improve the diagnosis of rare 
neurological disorders and improve access to treatments and potential specific disease-
modifying strategies.
Based on these premises, the Rare Movement Disorders Study Group of the International 
Parkinson and Movement Disorder Society (RMDSG) developed a survey, which was sent 
to all Society members, in order to assess accessibility to genetic testing by movement 
disorders clinicians from the five continents.
METHODS
Survey Design 
The RMDSG developed a 21-question online survey (Supplementary Material), which was e-
mailed to all 7815 members affiliated with the International Parkinson Disease and 
Movement Disorder Society (IPMDS). Responses were anonymous. The survey was 
launched with an introductory rationale and instructions. Data collection occurred over a 3-
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The survey included questions addressing the ease of access to general practitoners, 
general neurologists, movement disorders neurologists, paediatric neurologists, geneticists 
and genetic counsellors. It was inquired whether genetic testing for various types diseases 
manifesting with movement disorders (dystonias, parkinsonian disorders, choreas, 
cerebellar ataxias, hereditary spastic paraplegias (HSP), metabolic disorders and other 
genetic disorders) was offered. In addition to access to disease-specific tests, the availability 
of WES was evaluated. Finally, a set of answers explored access to geneticist consultation 
to interpret ambiguous genetic test results, the availability of a genetic national network, and 
the means of funding for genetic testing. 
To assess geographic variability, 7 regions were defined: North America, Central (including 
Caribbean) and South America, Europe, Middle East, Africa, Asia and Oceania. This study 
did not require approval of an ethics committee nor informed consent, as no human subjects 
or human biological material was used, and only the anonymous responses to the survey 
were analyzed [9].
Statistical analysis 
We used descriptive statistics to summarize demographics, means, and standard deviations 
for continuous variables, as well as frequencies and proportions for categorical variables. 
Differences between groups of quantitative data were assessed by Student’s t-test and 
ANOVA as required. Differences between proportions were explored through the use of the 
Chi-squared test (Yates corrected). Conditional on significant p-values, post-hoc chi-square 
tests were applied to compare frequencies distribution between each region respectively 
with Europe and North America, which were also compared between each other (total of 11 
comparisons for each variable); accordingly, Bonferroni’s correction was applied, and 
significance level was set at p ≤ 0.004. Access to and availability of different resources (e.g. 
access to practitioners; availability of genetic testing, etc.) were expressed in terms of rate 
ratios. Accessibility to general practitioners (GPs) and access to chorea testing were taken 
as the references in the calculation of the rate ratios mentioned above. The Katz logarithmic 
method was applied to calculate the 95% confidence interval corresponding to each of these 
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DATA SHARING
The data of this study are available from the corresponding author upon reasonable request.
RESULTS
Demographics
1269 surveys were received from 109 countries from all continents, resulting in an overall 
response rate of 16%. Most of respondents practiced in Europe, Asia, and North America 
(North America = 228; Central-South America = 167; Europe = 382; Africa = 72; Asia = 237; 
Oceania = 28; Middle East 45). The country of practice was not indicated by 110 
respondents and their surveys were not included in the analysis comparing world regions. 
75% of respondents answered all questions. The majority of respondents identified 
themselves as movement disorders specialists (n=877; 76%) (Supplementary Table 1). 
Movement disorders specialists represented >50% of participants in each region, with 
Europe having the highest percentage (> 85%). More than 50% of respondents spent their 
practice seeing patients with movement disorders. 39% practiced in a university setting, 26% 
in a combined (private practice/university setting), 21% in a government setting, 10% in 
private practice, and 4% in another setting.
Access to health care professionals and genetic testing
Access to a geneticist or genetic counsellor was often challenging or absent. Rate ratio 
analysis, taking general practitioners (GPs) as reference, showed that genetic specialists 
were 25-33-fold less accessible than GP (Supplementary Table 2).
When analyzing different regions (easy vs challenging/no access) (figure 1A), 
challenging/absent access to general neurologists was more frequently reported by 
respondents from Africa, Asia, Central/South America and Oceania compared to Europe and 
North America. Access to movement disorders and pediatric neurologists (figure 1A) as well 
as to geneticists and genetic counsellors (figure 1B) was more frequently reported to be 
challenging/absent in Africa, Asia, Central/South America and Middle East compared to 
Europe and North America. Overall, Africa and North America represented the two extremes 
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Genetic testing was offered in the institution of 46% of respondents. For 68% genetic testing 
was available in their city and for 87% it was available in their country. 
Overall, availability of genetic testing was low, with rate of access lower than 50%. Genetic 
testing for chorea was the most commonly available (408/943, 43%), followed by ataxias 
(373/931, 40%), dystonias (310/894, 35%), parkinsonian disorders (320/939, 34%), 
metabolic disorders (296/887, 33%), HSP (244/900, 27%) and other movement disorders 
(193/867, 22%). There was significantly lower access for all other tests relative to chorea 
(p<0.0001) (Table).
Genetic testing was more accessible in Europe and North America, with a significant 
imbalance in the availability with respect to the other regions, except for chorea testing 
(Figure 2). The lowest values for access were reported in Africa for dystonia testing (1%) 
and the highest for parkinsonisms testing in North America (53%). For parkinsonisms, 
dystonias, ataxias, HSP and metabolic disorders, there was significantly limited access to 
genetic testing in Africa, Asia, Central-South America compared to Europe and North 
America (p<0.004 for all comparisons). Genetic testing for dystonias (p=0.002) and 
metabolic disorders (p<0.0001) was more frequently available in Europe compared to North 
America (Figure 2). For any other genetic testing (as per question 10 of the survey), 
respondents from Europe reported more frequently access compared to all regions including 
North America (p<0.004 for all comparisons).  Fewer than 5% of respondents from Oceania 
and the Middle East could access testing for chorea, dystonia, ataxia, HSP and metabolic 
disorders. However, due to the small sample size of these groups, differences with Europe 
and North America were not statistically significant. 
Access to WES was reported by only 23% (208/885) of respondents and was significantly 
more accessible in Europe and North America compared to Africa, Asia, Central/South 
America and Middle East (p≤0.004) (Figure 3).
Only 30% of respondents reported that they had easy access to expert genetic interpretation 
of ambiguous results, with significant variations across regions (p<0.0001). All regions, 
except Oceania, had more challenging access to genetic consultation compared to Europe 
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national network for genetic testing in their country, and 44.2% of these were from Europe 
(Figure 4B). 
Financial barriers to genetic testing
Testing was reported to be available for free for individuals who could not afford it, only by 
31% of the respondents. In most cases (58%), genetic testing was covered by either private 
or public funding (due to overlapping payment mechanisms), followed by research funding 
(16%), private funding (14%), public funding (9%). The source of funding was unknown for 
4% of respondents. 
With respect to the source of funding for genetic testing, there were no significant 
differences between Europe and North America and each one of the other regions (Figure 
5A). Often, in each region, genetic testing was supported by a mixture of private and public 
funding. Yet, in Europe, genetic testing was free of charge according to 63% of respondents. 
In North America, Africa, Central/South America, Asia and Middle East access to free of 
charge genetic testing was by far significantly lower compared to Europe (Figure 5B).
DISCUSSION 
Over the last decade, major advances in gene identification have led to the delineation of 
hundreds of variants linked to many diseases manifesting with movement disorders [10]. 
Genetic diagnosis can be relevant for symptomatic treatment  [11], for prognosis and for 
family counselling, as in Huntington’s disease (HD). Moreover, although being far from 
genotype-specific treatment options  [12], experimental trials targeting the products of gene 
abnormalities are currently ongoing in HD [13] and Parkinson’s disease associated with 
glucocerebrosidase [14] or LRRK2 variants [15]. However, despite the increasing availability 
of modern genetic tests which allow simultaneous testing of many gene variants at a lower 
cost compared to traditional individual gene tests, there is minimal access to genetic testing 
in clinical practice at the worldwide level for the majority of movement disorders.
This survey, designed by the RMDSG, identified major challenges in accessing genetic 
testing in clinical practice. Main challenges were related to the availability of testing and 
access to specialist health professionals with expertise in interpreting a specific test result. 
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Despite growing numbers of gene variants reported to be associated with childhood and 
adulthood onset movement disorders [16], access to geneticists and genetic counselling was 
limited in all regions compared to Europe and North America. However, even in these 
relatively resource-rich areas, more than 50% of respondents experienced such challenges. 
When considering genetic testing for specific movement disorders, inequality of access was 
striking, except for chorea testing, for which access was more uniform across regions, albeit 
at low values. The broad availability of testing for HD explains this result, given the rarity of 
the other genetic choreas and also considering the HD gene was the first gene discovered in 
people with movement disorders  [17].  Specifically, responses from Africa, Asia and 
Central/South America reflected the lack of access to genetic testing for all other movement 
disorders, compared to Europe and North America. The level of access to genetic testing did 
not necessarly mirror the response rate in each region, as the number of respondents from 
Asia and Central/South America was comparable to North America. Lack of access to 
genetic testing for different movement disorders was also reported in Oceania and the 
Middle East, but comparisons did not reach statistical significance. Data from these regions 
should be interpreted cautiously, given the small number of respondents that did not allow 
meaningful comparisons. 
A similar result, highlighting differences between Europe and North America and the rest of 
the world, was obtained when inquiring about WES. This technology involves sequencing of 
the protein coding regions of the whole human genome, which requires a high level of 
expertise and bioinformatic resources for deidentified data processing and storage. More 
importantly, interpretation of genetic data and correlation with the clinical phenotype 
demands a mutual exchange of clinical and genetic information [18]. The interaction 
between the neurologist and the neurogeneticist is crucial for the interpretation of WES 
results, specifically in case of variants of unknown significance, secondary or unexpected 
findings. Also, WES might fail in detecting copy-number variants and repeat expansions [19] 
and negative results require careful discussion with expert professional figures. However, 
despite technological developments, we demonstrated poor access not only to geneticists or 
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most of world regions compared to Europe and North America. More importantly, in case of 
ambiguous results from genetic testing, access to geneticists was reported challenging or 
not available in Africa, Asia, Central/South America and Middle East compared to North 
America and Europe. 
Over the past years, scientific societies have promoted a series of initiatives to assist 
clinicians when dealing with genetic disorders such the Movement Disorder Society Genetic 
mutation database (MDSGene) [16, 20]. This instrument includes data on more than 1651 
different mutations from 6628 movement disorder patients extracted from 1250 publications 
[13] and is constantly being updated. Such databases provide aids to clinical diagnosis, 
especially when genetic consultation is not available to discuss results. There are many 
other resources which could be developed to improve access to genetic testing, including 
development of national or international genetic networks which might produce a guide on 
how to approach genetic diagnosis, from listing available certified laboratories to 
harmonizing next generation sequencing panels for specific disorders. 
In addition to the lack of genetic expertise in different regions, financial/economic barriers 
also play a significant role in inequality of access. Whereas the majority of European 
respondents reported that genetic testing was performed for free, this was not the case for 
the other regions, including North America. Specifically, this region encompassed Canada 
and United States, which have, respectively, a public- and insurance-based healthcare 
system. Higher per capita income and health insurance coverage might explain why United 
States respondents reported more access to genetic testing. It is critical to improve 
availability and to promote lower costs for testing, in addition to improving access to expert 
interpretation of test results. 
Our results revealed inequality of access to genetic testing at a worldwide level and overall a 
challenging access in more than half of cases for all types of testing, even in Europe and 
North America. These results are consistent with a survey promoted by the European 
Reference Network for Rare Neurological Diseases (ERN-RND) [21]. This survey collected 
responses from 80 European experts in atypical parkinsonism, dystonias/paroxysmal 
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was available in European countries, genetic investigations for HSP/ataxia and dystonia 
were difficult to access.
The data presented here expand previously reported findings and provide novel data about 
genetic testing accessibility in different world regions obtained from a large sample of 
respondents (1269 from 109 countries). Online surveys are a generally accepted 
investigational method [22], with many advantages, including the opportunity to access a 
large sample of individuals, cost-efficiency, automation and real time access, and 
convenience for respondents. The limitations of this method include sampling methods, 
accuracy, ambiguity when interpreting some questions and the inability to properly validate 
the provided information [23]. The estimated average response rate for online surveys is 
highly variable, ranging from 20-30%, and the minimum acceptable response rate still under 
discussion in the literature. Our survey had a good worldwide representation (respondents 
from 109 countries) with an overall response rate of 16.2%. This rate is higher compared to 
a recent survey paper on functional movement disorders administered to IPMDS members 
(864 responses out of 7689 members from 92 countries, 11% response rate) [24]. 
In conclusion, our survey paper explored availability and accessibility of genetic testing for 
movement disorders worldwide, highlighting frequently challenging access but also major 
inequalities between Europe and North America and the rest of the world. Future studies will 
help to identify the real and practical needs for advances in diagnosis, testing, and potential 
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LEGENDS TO FIGURES
Figure 1. A) Access to general neurologists, movement disorders (MDS) neurologists and 
pediatric neurologists in different world regions. B) Access to geneticists and genetic 
counsellors in different world regions. *significant differences compared to Europe, p≤0.004. 
#significant differences compared to North America, p≤0.004. Number or respondents for 
each item are shown in x-axis.
Figure 2. Access to genetic testing for parkinsonism, chorea, dystonia, ataxia, hereditary 
spastic paraplegia (HSP), metabolic disorders across world regions (question #10: Do you or 
your institution offer any of the following genetic testing?). *significant differences compared 
to Europe, p≤0.004. #significant differences compared to North America, p≤0.004. 
§significant difference between Europe and North America, p≤0.004. Number or 
respondents for each item are shown in x-axis.
Figure 3. Poor access to whole exome sequencing (WES) in all world regions compared to 
Europe and North America. *significant differences compared to Europe, p≤0.004. 
#significant differences compared to North America, p≤0.004.  Number or respondents for 
each item are shown in x-axis.
Figure 4. A) Access to geneticists in case of ambiguous genetic test results. B) Presence of 
national genetic networks. *significant differences compared to Europe, p≤ 0.004. 
#significant differences compared to North America, p≤0.004. Number or respondents for 
each item are shown in x-axis.
Figure 5. A) Modality of funding for genetic testing for movement disorders across world 
regions. B) Access to free-of-charge genetic testing in different world regions. *significant 
differences compared to Europe, p≤0.0001.  Number or respondents for each item are 
shown in x-axis.
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Rate ratios and 95% confidence intervals (95% CI). Chi2: p<0.0001 – Linear trend p<0.0001.  
DISORDER RATE RATIO 95% CI (KATZ) 
CHOREA (REFERENCE) 1.00 ---- 
METABOLIC DISORDERS 1.02 0.94-1.11 
ATAXIAS 1.05 0.97-1.15 
DYSTONIAS 1.14 1.05-1.24 
OTHER GENETIC TESTS 1.19 1.09-1.28 
PARKINSONIAN DISORDERS 1.19 1.10-1.28 
HEREDITARY SPASTIC PARAPARESIS 1.23 1.14-1.33 
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